Most Recent
Costly IP cases could make Australian courts look bad, Dynastat patent judge says
Biopharmalex 2020-02-26 5:52 pm By Miklos Bolza Sydney

A judge overseeing patent litigation over the painkiller Dynastat has urged the parties to narrow any issues in dispute, saying the excessive amounts of money spent in these types of cases could harm public perception.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Wyeth loses privilege claim over Allens docs in Merck’s vaccine patent case
Allens 2019-10-01 3:56 pm By Miklos Bolza Sydney

Wyeth has lost a bid to claim legal professional privilege over certain documents sought by Merck Sharp & Dohme as the two rivals head towards a hearing for the reopening of the Prevnar 13 patent case.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer may seek stay of Merck vaccine patent case
Allens 2019-08-21 3:53 pm By Miklos Bolza Sydney

Global pharmaceutical firm Pfizer is mulling an application to stay a lawsuit by Merck Sharp & Dohme seeking to invalidate a patent related to the blockbuster Prevnar 13 vaccine as it awaits the outcome of similar proceedings in the US.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Claims of stolen docs at heart of new suit against Pfizer over vaccine patent
Allens 2019-07-16 9:48 pm By Miklos Bolza Sydney

Merck Sharp & Dohme has claimed ownership of a Pfizer patent related to the blockbuster Prevnar 13 vaccine, after a doctor who moved between the pharmaceutical companies and is listed as an author on the patent allegedly accessed confidential Merck documents before jumping ship to Pfizer.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

InterPharma loses bid to invalidate Pfizer’s Precedex patent
Campbell Thompson 2019-06-24 11:54 am By Miklos Bolza Sydney

Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?